9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Estimated reading time: < 1 min

Condition: Locally Advanced or Metastatic Solid Tumor

Estimated Enrollment: 117

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Adverse Events (Part 1 and Part 2),  Objective response rate (ORR) (Part 2),  Maximum observed concentration (Cmax) of rebastinib, Area under the concentration-time curve (AUC) of rebastinib

Interventions: rebastinib, Carboplatin

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Sequential Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: November 1, 2020

Completion Date: November 1, 2020

Last  Posted Date: May 23, 2019

Location: University of California San Francisco (UCSF), San Francisco, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT03717415

Was this article helpful?
Dislike 0